6 Review of guidance

6 Review of guidance

6.1 NICE proposes that the guidance on this technology is considered for review by the Guidance Executive when data from the phase III SOLO‑2 study becomes available or after 2 years, whichever is sooner.

Andrew Dillon
Chief Executive
January 2016

  • National Institute for Health and Care Excellence (NICE)